Strand Life Sciences, a company backed by Reliance, has won an Indian patent for a blood test platform aimed at finding cancer early. The test needs one blood draw and reads the DNA that tumors and other cells shed into the bloodstream.
For a patient, that could mean a screening visit with no biopsy needle and no tissue sample. Whether it works as well as it sounds is something the patent alone cannot say, and no performance figures came with the news.
What the platform reads
The system looks at cell-free DNA, small fragments that float in the blood. These fragments are sequenced to a high standard, with strict quality control built in, so the software can pull out two kinds of signal. One is methylation, a chemical pattern on DNA. The other is fragmentomics, which is about the features of the fragments themselves.
Machine learning algorithms then work through that data. According to the reports, the aim is twofold: to spot cancer, and to estimate which tissue it started in. Doctors who know where a cancer began can aim their scans and treatment sooner, which matters to anyone waiting for answers.
Methylation changes are a classic hallmark of early-stage cancer. Older screening methods often miss these faint shifts across the genome. Strand says its patented system captures them widely and with minimal loss, which is the property that makes a blood-based screen sensitive enough to be useful.
The case for India
India sees more than 1.5 million new cancer cases a year, and many are caught late, when treatment choices are narrow. Strand’s pitch is that falling sequencing costs let the test scale, and that it can do so without new hospital infrastructure, which would put screening within reach of far more regions.
The patent covers the method itself. No date has been given for when the test might be offered to patients.
